If you invest in bio-tech you should consider Amarantus Bioscience -AMBS - currently under a dime.
The company recently launched its diagnostic test, LymPro, that detects early stage Alzheimer's. Potential $3B annual market.
The company also has several orphan indications for its patented drug MANF.
Read yesterday's Yahoo news for AMBS.
Amarantus Bioscience - AMBS - Currently trading under a dime.
Partnership for the company's diagnostic blood test to detect early stage Alzheimer's expected to be announced soon. Potential $500M annual market with no competition.
Twitter: @AmarantusBio .... 10,000 followers.